

## **Mallia Secures European Patent Covering sCD83 for Hair Growth and Wound Healing**

- In addition to hair growth, patent also covers topical and systemic applications of sCD83 for wound healing, hair and skin care
- Patent strengthens Mallia Therapeutics' development of a novel treatment that modulates local inflammation and activates hair follicle stem cells

**Erlangen, Germany, June 11, 2025** – Mallia Innovations GmbH today announced that the European Patent Office (EPO) has granted a patent for the use of the soluble CD83 (sCD83) protein for hair growth, wound healing, hair and skin care. This patent covers the therapeutic and cosmetic application of sCD83, which has demonstrated strong potential in promoting hair growth through a multimodal mode of action.

European Patent No. 4,135,745 encompasses the local and systemic use of sCD83 for therapeutic hair growth applications, which could help treat conditions such as androgenetic alopecia (AGA) and alopecia areata (AA), and therapeutic wound healing, for instance in patients with chronic diabetic wounds and hard to heal wounds. Further, the patent covers cosmetic use of sCD83, which could help people desiring fuller hair and/or longer eyelashes. sCD83 operates via multimodal mechanisms: it induces an anti-inflammatory environment at the hair follicle, inhibits its cell death and directly stimulates follicular stem cells, promoting new hair growth and strengthening hair thickness.

sCD83 was first discovered more than 20 years ago by Mallia-cofounder Prof. Dr. Alexander Steinkasserer, Head of the Department of Immune Modulation at Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), as an immune modulating molecule.<sup>1</sup> His work led to the discovery of the wound-healing properties of sCD83 as well as to the serendipitous finding of its potent hair growth-promoting function.<sup>2</sup> The patent was granted to the Friedrich-Alexander-Universität Erlangen-Nürnberg and Mallia Innovations is the exclusive license holder.

“Securing this patent is a significant milestone for Mallia and confirms the novelty of our approach,” said **Prof. Dr. Alexander Steinkasserer, Co-founder and Managing Director of Mallia Innovations**. “sCD83 has potential to be developed as novel therapeutics and cosmetic products to help people suffering from hair loss, chronic wounds or simply desiring to improve their hair thickness. This strengthens the ongoing development efforts of Mallia, from therapeutic solutions for patients to science-based cosmetic care.”

“As President, I am not only proud of our researchers' strength in innovation, but also of the entrepreneurial spirit at FAU,” added **Prof. Dr. Joachim Hornegger, President of Friedrich-Alexander-Universität Erlangen-Nürnberg**. “Companies like Mallia that emerge from the research environment at FAU are an important part of the innovation ecosystem in the Metropolitan Region. I would like to wish Professor Steinkasserer all the very best and continued success with his company.”

Mallia's preclinical studies have shown that topical application of sCD83 can effectively stimulate hair growth without systemic side effects, addressing the limitations of current treatments that can involve side effects such as systemic immunosuppression.

## About sCD83

Soluble CD83 (sCD83) is an immunomodulatory protein that is currently being developed for the topical treatment of hair loss (MAL-856) and stimulation of hair growth (MAL-838). The soluble CD83 protein was first identified in 2001 by Mallia co-founder Prof. Dr. Steinkasserer. It has anti-inflammatory properties via the induction of inflammation resolution, which promotes wound healing and induces new hair growth.<sup>2</sup> In addition, sCD83 has been shown to activate regulatory T cells (Tregs)<sup>3</sup>, which interact directly with hair follicles and can activate them.<sup>4</sup> Furthermore, sCD83 inhibits cell death of hair follicles and directly activates follicular stem cells, thereby stimulating new hair growth. This multimodal mode of action distinguishes sCD83 from other topically applied hair growth agents.

Topically applied, sCD83 can directly reach the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a major advantage over systemic treatment options, which can cause severe side effects.

## About hair loss

Hormone-related hair loss in men and women (androgenetic alopecia, or AGA) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of women post menopause are affected by androgenetic alopecia. Another 147 million people suffer from immune-related, circular hair loss (alopecia areata, or AA<sup>5,6</sup>).

Androgenetic alopecia usually progresses gradually and is due to genetic and hormonal factors. In men, it often leads to a receding hairline and baldness on the top of the head, while in women it causes thinning hair in the parting area. Alopecia areata causes circular hair loss on the scalp, face or other parts of the body. It occurs when the immune system erroneously attacks hair follicles, leading to immune-mediated hair loss.

## About Mallia

**Mallia Innovations GmbH**, based in Erlangen, Germany, is the holding company strategically driving the development and commercialization of cosmetic applications and biopharmaceutical therapies of the immune modulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing.

Subsidiary **Mallia Aesthetics GmbH** focuses on the development of cosmetic products to stimulate hair growth. Based on the sCD83 protein, innovative cosmetic products are being developed and marketed to specialists and consumers.

Subsidiary **Mallia Therapeutics GmbH** focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions. Mallia Therapeutics' approach is also based on the scientifically proven immune modulatory mode of action of sCD83, which has been investigated for more than 25 years by Mallia co-founder Prof. Dr Alexander Steinkasserer.<sup>1</sup>

For more information, visit [www.mallia.com](http://www.mallia.com), follow us on [LinkedIn](#), and contact MC Services for high resolution pictures of the leadership team.

### **Mallia Contact:**

Mallia Innovations GmbH  
[info@mallia.com](mailto:info@mallia.com)

### **International media contact:**

MC Services AG  
Dr. Regina Lutz / Katja Arnold  
Tel.: +49 (0)89 210 228 0  
E-Mail: [mallia@mc-services.eu](mailto:mallia@mc-services.eu)

- 
- <sup>1</sup> Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., ... & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. *The Journal of experimental medicine*, 194(12), 1813-1821. DOI: [10.1084/jem.194.12.1813](https://doi.org/10.1084/jem.194.12.1813)
- <sup>2</sup> Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., ... & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. *Frontiers in Immunology*, 13, 1012647. DOI: [10.3389/fimmu.2022.1012647](https://doi.org/10.3389/fimmu.2022.1012647)
- <sup>3</sup> Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., ... & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. *The Journal of Immunology*, 191(4), 1965-1975. DOI: [10.4049/jimmunol.1201531](https://doi.org/10.4049/jimmunol.1201531)
- <sup>4</sup> Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., ... & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. *Cell*, 169(6), 1119-1129. DOI: [10.1016/j.cell.2017.05.002](https://doi.org/10.1016/j.cell.2017.05.002)
- <sup>5</sup> Feinstein, R. P. (2022). Androgenetic alopecia.: <https://emedicine.medscape.com/article/1070167-overview>
- <sup>6</sup> Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., ... & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. *Journal of Managed Care & Specialty Pharmacy*, 28(4), 426-434. DOI: [10.18553/jmcp.2022.28.4.426](https://doi.org/10.18553/jmcp.2022.28.4.426)